Miamicardiology.net

CURRICULUM VITAE

Paul H. Seigel, M.D., F.A.C.C.

PROFESSIONAL AFFILIATION:
Baptist Hospital of Miami

CURRENT LICENSE:

EDUCATION:

Medical College of Virginia
State University of New York at Binghamton
POST GRADUATE TRAINING:
Fellowship in Cardiovascular Medicine
College of Medicine and Dentistry of New Jersey
Residency in Internal Medicine

Page Two
Paul H. Seigel, M.D., F.A.C.C.
POST GRADUATE TRAINING CONTINUED.
Internship in Internal Medicine

CERTIFICATIONS AND EXAMS:
Diplomate of the American Board of Internal Medicine - Diplomate of the American Board of Cardiovascular Medicine - Diplomate of National Board of Medical Examiners -
ACEDEMIC APPOINTMENTS:

Florida International University, 2011-present

PRIVATE PRACTICE EXPERIENCE:
James Bierfeld, M.D.
Solo Practice
Associates in Cardiology
Miami Cardiology Group
Managing Partner
Page Three Paul H. Seigel, M.D., F.A.C.C. INVESTIGATIONS - RESEARCH:
Cardiovascular Research Center of South Florida TIMI-50 (Schering Plough) , A Multicenter, Randomized,
Double-Blind, Placebo-Controlled Study to Evaluate the Safety
and Efficacy of SCH530348 in Addition to Standard of Care in
Subject with a History of Atherosclerotic Heart Disease.
INVEST (Knoll Pharmaceuticals). Principal Investigator. This is
an international clinical trial comparing a calcium antagonist
(Verapamil Sinus rhythm) with a non-calcium antagonist treatment
strategy (Atenolol) for the control of hypertension in patients with
coronary artery disease.
T.N.T. (Treating to New Targets) Parke-Davis/Pfizer. Principal
Investigator. This study is to assess the CHD event reduction
efficacy and safety of low-density lipoprotein cholesterol lowering
to achieve LDL-C targets beyond currently recommended
minimums when compared to only achieving the minimum.
Drug Used: Atorvistatin 10 mg up to 80 mg in the double-blind CAMELOT (Pfizer, Inc). Principal Investigator. Comparison of
Amlodipine versus Enalapril to Limit Occurrences of Thrombosis.
GUSTO IV (Eli Lily and Co). Principal Investigator. This is a
post-MI study through the Cleveland Clinic.
BRAVO: Blockade of the GP IIB/IIA Receptor to Avoid Vascular
Occlusion. Principal Investigator.
PRESTO: Prevention of REStenosis by Tranilast and its
Outcomes. Principal Investigator. A phase III Double blind
Placebo Controlled Trial of three doses of Tranilast (Protocol
004).
MOXON TRIAL (Covance). Principal Investigator.
Page Four
Paul H. Seigel, M.D., F.A.C.C.
INVESTIGATIONS – RESEARCH (continued):

STARSHIP (AstraZeneca) A 6 week, Randomized, open-Label,
Comparative Sturdy to Evaluate the Efficacy and Safety of
Rosuvastatin
Hypercholesterolemia in Hispanic Subjects. ACTIVATE (SankyoPharma Development) A Randomized,
Double-Blind placebo Controlled Study of the Efficacy and Safety
of the ACAT inhibitorCS-505 versus Placebo for Reducing the
Progression of Atherosclerosis in Subjects with Known Coronary
Artery Disease Using Ultrasound (IVUS).
EVEREST (Otsuka Pharmaceuticals) A Randomized, Double-
blind Placebo-controlled Study to Evaluate the Long Term
Efficacy and Safety of Oral Tolvaptan Tablets in Subjects
Hospitalized with Worsening Congestive Heart Failure.
CHARISMA (Sanofinsynthelabo and Bristal Myers Squibb Co.)
Clopidogrel For High Atherothrombotic Risk and Ischemic
Stabilization, Management and Avoidance.
CP-529, 414 (Pfizer) A Randomized, Double-blind Study to
Evaluate the Efficacy, Safety, and Tolerability of Fixed
Combination
Angiographically Documented Coronary Artery Disease. LUNAR (AstraZeneca) A 12-Week, Randomized, Open-Label, 3-
Arm, Parallel Group, Multicenter, Phase IIIb Study Comparing the
Efficacy and Safety of Rosuvastatin 20 mg and 40 mg with that of
Atorvastatin 80 mg in Subjects with Acute Coronary Syndromes.
NEB 302 (Bertek Pharmaceuticals) A Double-blind, Multi-Center,
Randomized, Placebo-Controlled, Parallel Group Dosing Study
Evaluating the Effects of Nebivolol on Blood Pressure in Patients
with Mild to Moderate Hypertension.
NEB 306 (Bertek Pharmaceuticals) A Multi-Center, Parallel
Group Extension Study to Determine the Safety and Efficacy of
Long-Term Nebivolol Exposure in Patients with Mild to Moderate
Hypertension.
Page Five
Paul H. Seigel, M.D., F.A.C.C.
INVESTIGATIONS – RESEARCH (continued):

NEB 323 (Bertek Pharmaceuticals) A Multi-Center, Open
Extension Study to Assess the Safety and Efficacy of Long-Term
Nebivolol Exposure in Patients with Mild to Moderate
Hypertension.
COMPELL (Kos Pharmaceuticals) An Open-Label, Comparative
Efficacy Evaluation of Lipid Levels when Treated with Niaspan
and Statin or Other Lipid-Modifying Therapies.
MDT3-003 (Labopharm) A Four-Arm Study Comparing the
Analgesic Efficacy and Safety of Tramadol HCl Once a day 100,
200 and 300 mg Versus Placebo for the Treatment of Pain due to
Osteoarthritis of the Knee.
LECTURES/SYMPOSIUMS:

06/07 PRIMARY CARE SYMPOSIUM, Hawks Cay Resort
Topic Pre and Post Operative Evaluation of a Cardiac Patient 06/09 PRIMARY CARE SYMPOSIUM, Hawks Cay Resort
2007-Present PEER Group, Various locations.
For: Astra-Zeneca (Atacand) and Forest Labs (Bystolic)
PROFESSIONAL ORGANIZATIONS:

REFERENCES:

Source: http://www.miamicardiology.net/images/uploaded/mcg/Seigel.CV.2013.pdf